全文获取类型
收费全文 | 203083篇 |
免费 | 28550篇 |
国内免费 | 6732篇 |
专业分类
耳鼻咽喉 | 1696篇 |
儿科学 | 1482篇 |
妇产科学 | 5157篇 |
基础医学 | 14523篇 |
口腔科学 | 2161篇 |
临床医学 | 16160篇 |
内科学 | 19536篇 |
皮肤病学 | 1360篇 |
神经病学 | 724篇 |
特种医学 | 5978篇 |
外国民族医学 | 253篇 |
外科学 | 30037篇 |
综合类 | 26130篇 |
现状与发展 | 38篇 |
一般理论 | 3篇 |
预防医学 | 9519篇 |
眼科学 | 110篇 |
药学 | 14301篇 |
131篇 | |
中国医学 | 4879篇 |
肿瘤学 | 84187篇 |
出版年
2024年 | 186篇 |
2023年 | 4206篇 |
2022年 | 6034篇 |
2021年 | 10533篇 |
2020年 | 10539篇 |
2019年 | 9527篇 |
2018年 | 9153篇 |
2017年 | 9552篇 |
2016年 | 10293篇 |
2015年 | 11875篇 |
2014年 | 17207篇 |
2013年 | 16878篇 |
2012年 | 13618篇 |
2011年 | 13818篇 |
2010年 | 10056篇 |
2009年 | 10309篇 |
2008年 | 10500篇 |
2007年 | 9826篇 |
2006年 | 8668篇 |
2005年 | 7054篇 |
2004年 | 5857篇 |
2003年 | 4847篇 |
2002年 | 4103篇 |
2001年 | 3748篇 |
2000年 | 3095篇 |
1999年 | 2553篇 |
1998年 | 1980篇 |
1997年 | 1738篇 |
1996年 | 1411篇 |
1995年 | 1481篇 |
1994年 | 1221篇 |
1993年 | 937篇 |
1992年 | 829篇 |
1991年 | 753篇 |
1990年 | 563篇 |
1989年 | 511篇 |
1988年 | 422篇 |
1987年 | 379篇 |
1986年 | 288篇 |
1985年 | 381篇 |
1984年 | 311篇 |
1983年 | 198篇 |
1982年 | 204篇 |
1981年 | 188篇 |
1980年 | 164篇 |
1979年 | 114篇 |
1978年 | 76篇 |
1977年 | 60篇 |
1976年 | 54篇 |
1975年 | 34篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
Idris Olasunmbo Ola Kirsi Talala Teuvo Tammela Kimmo Taari Teemu Murtola Paula Kujala Jani Raitanen Anssi Auvinen 《International journal of cancer. Journal international du cancer》2023,152(4):672-678
Prostate-specific antigen (PSA)-based screening for prostate cancer (PCa) can reduce PCa mortality, but also involves overdetection of low-risk disease with potential adverse effects. We evaluated PCa incidence among men with PSA below 3 ng/mL and no PCa diagnosis at the first screening round of the Finnish Randomized Study of Screening for PCa. Follow-up started at the first screening attendance and ended at PCa diagnosis, emigration, death or the common closing date (December 2016), whichever came first. Cox regression analysis was used to estimate hazard ratios and their confidence intervals (CI). Among men with PSA <3 ng/mL, cumulative PCa incidence was 9.1% after 17.6 years median follow-up. Cumulative incidence was 3.6% among men with baseline PSA 0 to 0.99 ng/mL, 11.5% in those with PSA 1.0 to 1.99 ng/mL and 25.7% among men with PSA 2 to 2.99 ng/mL (hazard ratio 9.0, 95% CI: 7.9-10.2 for the latter). The differences by PSA level were most striking for low-risk disease based on Gleason score and EAU risk group. PSA values <1 ng/mL indicate a very low 20-year risk, while at PSA 2 to 2.99 ng/mL risks are materially higher, with 4- to 5-fold risk for aggressive disease. Using risk-stratification and appropriate rescreening intervals will reduce screening intensity and overdetection. Using cumulative incidence of clinically significant PCa (csPCa) as the criterion, rescreening intervals could range from approximately 3 years for men with initial PSA 2 to 2.99 ng/mL, 6 years for men with PSA 1 to 1.99 ng/mL to 10 years for men with PSA <1 ng/mL. 相似文献
72.
Lina Jansen Lars Schwettmann Christian Behr Andrea Eberle Bernd Holleczek Christina Justenhoven Hiltraud Kajüter Kirsi Manz Frederik Peters Ron Pritzkuleit Andrea Schmidt-Pokrzywniak Eunice Sirri Fabian Tetzlaff Sven Voigtländer Volker Arndt 《International journal of cancer. Journal international du cancer》2023,153(10):1784-1796
Age-standardized cancer incidence has decreased over the last years for many cancer sites in developed countries. Whether these trends led to narrowing or widening socioeconomic inequalities in cancer incidence is unknown. Using cancer registry data covering 48 million inhabitants in Germany, the ecological association between age-standardized total and site specific (colorectal, lung, prostate and breast) cancer incidence in 2007 to 2018 and a deprivation index on district level (aggregated to quintiles) was investigated. Incidence in the most and least deprived districts were compared using Poisson models. Average annual percentage changes (AAPCs) and differences in AAPCs between deprivation quintiles were assessed using Joinpoint regression analyses. Age-standardized incidence decreased strongly between 2007 and 2018 for total cancer and all cancer sites (except female lung cancer), irrespective of the level of deprivation. However, differences in the magnitude of trends across deprivation quintiles resulted in increasing inequalities over time for total cancer, colorectal and lung cancer. For total cancer, the incidence rate ratio between the most and least deprived quintile increased from 1.07 (95% confidence interval: 1.01-1.12) to 1.23 (1.12-1.32) in men and from 1.07 (1.01-1.13) to 1.20 (1.14-1.26) in women. Largest inequalities were observed for lung cancer with 82% (men) and 88% (women) higher incidence in the most vs the least deprived regions in 2018. The observed increase in inequalities in cancer incidence is in alignment with trends in inequalities in risk factor prevalence and partly utilization of screening. Intervention programs targeted at socioeconomically deprived and urban regions are highly needed. 相似文献
73.
目的:探讨细胞骨架调节剂(lncRNA cytoskeleton regulator,CYTOR)是否通过靶向调控miR-503来促进细胞周期蛋白E1(cyclin E1,CCNE1)影响上皮性卵巢癌增殖。方法:实时定量聚合酶链反应(RT-qPCR)检测CYTOR在不同临床分期、病理分级和有无淋巴结转移患者人上皮性卵巢癌组织、癌旁组织和正常组织以及不同卵巢癌细胞中的表达;starBase数据库(网址:http://starbase.sysu.edu.cn/)预测分析CYTOR和miR-503以及miR-503与CCNE1之间的关系,同时荧光素酶实验进行验证;RT-qPCR和免疫荧光分别检测miR-503与CCNE1在人上皮性卵巢癌组织、癌旁组织和正常组织以及不同卵巢癌细胞中的表达;RNA转染技术在A2780中细胞分别沉默CYTOR、过表达miR-503和沉默CCNE1表达,CCK-8检测各组细胞增殖能力变化;RT-qPCR和免疫荧光检测沉默CYTOR后miR-503和CCNE1的表达以及过表达miR-503后CCNE1的表达。结果:CYTOR和CCNE1在上皮性卵巢癌组织中表达增加,同时在临床分期III-IV期、病理分级G_(3)级、淋巴结转移阳性患者肿瘤组织中表达同样显著增加且导致卵巢癌患者术后预后较差;通过数据库分析CYTOR可直接靶向抑制miR-503,而miR-503可直接靶向抑制CCNE1表达,双荧光素酶实验结果与之相同;CYTOR和CCNE1促进上皮性卵巢癌增殖,而miR-503抑制上皮性卵巢癌增殖作用。结论:lncRNA CYTOR通过调控miR-503/CCNE1轴促进上皮性卵巢癌的增殖。 相似文献
74.
Shantata Kudchadkar Safia Ahmed Tanmoy Mukherjee Jayesh Sagar 《World journal of gastrointestinal oncology》2022,14(4):833-841
Incidence of colorectal cancer (CRC) is on rise. While approximately 70% of all CRC cases are sporadic in nature, 20%-25% have familial aggregation and only < 5% is hereditary in origin. Identification of individuals with hereditary predi lection for CRC is critical, as it has an impact on their overall surgical mana gement including surgical timing, approach & technique and determines the role of prophylactic surgery and outcome. This review highlights the concept of hereditary CRC, provides insight into its molecular basis, possibility of its application into clinical practice and emphasizes the current treatment strategies with surgical management, based on the available international guidelines. 相似文献
75.
76.
《Cancer cell》2022,40(10):1223-1239.e6
77.
78.
《European journal of surgical oncology》2022,48(5):1104-1109
BackgroundThis study aimed to describe the treatment of metachronous colorectal cancer metastases in a recent population-based cohort.MethodPatients with stage I-III colorectal cancer (CRC), diagnosed between January 1st and June 30th, 2015 who were surgically treated with curative intent were selected from the Netherlands Cancer Registry. Follow-up was at least 3 years after diagnosis of the primary tumour. Treatment of metachronous metastases was categorized into local treatment, systemic treatment, and best supportive care. Overall survival was estimated using Kaplan-Meier method.ResultsOut of 5412 patients, 782 (14%) developed metachronous metastases, of whom 393 (50%) underwent local treatment (LT) with or without systemic therapy, 30% of patients underwent only systemic therapy (ST) and 19% only best supportive care (BSC). The most common metastatic site was the liver (51%) followed by lungs (33%) and peritoneum (22%). LT rates were 69%, 66%, and 44% for liver-only, lung-only and, peritoneal-only metastases respectively. Patients receiving LT and ST were significantly younger than patients receiving LT alone, while patients receiving BSC were significantly older than the other groups (p < 0.001). Patients with liver-only or lung-only metastases had a 3-year OS of 50.2% (43.3–56.7 95% CI) and 61.5% (50.7–70.6 95% CI) respectively. Patients with peritoneal-only disease had a lower 3-year OS, 18.1% (10.1–28.0 95% CI).ConclusionPatients with metastases confined to the liver and lung have the highest rates of local treatment for metachronous metastatic colorectal cancer. The number of patients who underwent local treatment is higher than reported in previous Dutch and international studies. 相似文献
79.
80.